Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Glioblastoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 10Azacitidine 10fludarabine phosphate 8Whole-Body Irradiation 8Cyclosporine 7ruxolitinib 6Mycophenolic Acid 6Busulfan 6Methotrexate 5Cyclophosphamide 5fludarabine 4Tacrolimus 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 3Alemtuzumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2eprenetapopt 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Docetaxel 2Cord Blood Stem Cell Transplantation 2tipifarnib 1sonidegib 1rucaparib 1quizartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloproliferative Disorders × Captopril × Clear all
NCT04629651 2023-10-11

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡